IDEAYA Biosciences reported its third‑quarter 2025 financial results, posting a net income of $119.2 million for the three months ended September 30, 2025, compared with a net loss of $77.5 million in the prior quarter. The company’s cash, cash equivalents and marketable securities balance increased to $1.14 billion, up from $991.9 million at the end of June.
The company’s earnings per share were $1.35, surpassing the consensus estimate of –$0.47. Total revenue for the quarter was $207.8 million, far exceeding the $5.97 million estimate. Collaboration revenue accounted for $207.8 million, driven by a $210 million upfront payment from Servier and ongoing research‑and‑development service revenue under a new exclusive license for darovasertib.
The Servier partnership, announced in the same release, extends IDEAYA’s cash runway to 2030 and provides a pathway for commercializing darovasertib outside the United States. The $210 million upfront payment, coupled with future collaboration revenue, positions the company to accelerate its clinical programs and broaden its market reach.
IDEAYA’s pipeline remains robust, with darovasertib advancing in Phase 2/3 OptimUM‑02 for uveal melanoma and other clinical‑stage candidates such as IDE397, IDE849 and IDE892. The company has received IND clearance for IDE892 and is on track for additional IND filings.
Management indicated that the company will continue to generate collaboration revenue and maintain its cash runway through 2030, while investing in its clinical development program. No specific revenue or expense guidance for the next quarter was disclosed.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.